Feeds:
Posts
Comments

Archive for the ‘Schering’ Category

*****
Note: there will be no Impactiviti Daily for the remainder of this week, as I’ll be away at a conference…

TODAY’S NEWS

Biotech: finally profitable – The biotechnology industry is finally profitable, according to a new report out today from Ernst & Young. The report states that biotech companies in the world’s largest hubs — the United States, Europe, Canada and Australia — achieved collective profitability in 2009, marking the first year the industry has ever crossed into the black. The companies in those regions posted an aggregate net profit of $3.7 billion in 2009, compared to a net loss of $1.8 billion in 2008…more

Making quite a living as a pharma whistleblower – drug rep hits the legal lottery twice.

Merck to close three NJ facilities – not a big surprise, post-merger with Schering.

RECOMMENDED

Managed Care/Managed Markets Training – The need is growing, not shrinking. Proven and successful programs are available from Impactiviti’s partner network.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

What are we Doing….Really?

JUST FOR FUN

You really can’t make stuff like this up: Handyman injured after chopping down branch he leaned ladder against.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

*****

TODAY’S NEWS

Merck, Schering, Merger, Management, Munificence – it pays to be an exec at an acquired pharmaco.

What’s on the the docket for biotechs in the coming quarter? A nice, quick summary.

Kids’ suicide risk appears to be level across all anti-depressants. Now:  what about the risk of untreated depression??

RECOMMENDED

Software training – Do your employees need training on software programs? The Impactiviti Partner Network is your resource if you’re looking for a great provider.  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Plus: What’s the Single Answer to Pharma’s biggest Digital Marketing Questions? I agree with Wendy Blackburn here.

JUST FOR FUN

Sand and Water. Some fabulous sand sculptures. Plus, eye-catching (even eerie) pictures of running water.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Visit the Impactiviti Job Board

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

*****

Read Full Post »

TODAY’S NEWS

Ouch – more NJ pharma job cuts – Call it the proverbial one-two punch. On Jan. 31, Pfizer expects to chop 400 jobs from Monmouth Junction, where Wyeth maintained research offices. And on Feb. 9, Merck will eliminate 500 jobs from Kenilworth, where Schering-Plough had its headquarters, although it’s not clear which types of jobs will be affected...more

Cephalon‘s jet lag pill not ready for takeoff – For those of you who were unaware, Cephalon is anxiously awaiting FDA approval to sell Nuvigil, a slightly modified form of its Provigil narcolepsy pill, to combat jet-lag disorder. The drugmaker had hoped for a regulatory okay last month, but the agency delayed a decision in order to review datamore. After recent airline news, maybe they should rename it NuVigilant and package it for TSA inspectors…

Anemia drugs – FDA says let’s take a look at safety. Again.
RECOMMENDED

Simulations. It takes solid expertise and creativity to make great eLearning simulations. And our network has the providers you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Roll your own Future. An encouragement to actively shape your professional trajectory.

JUST FOR FUN

Feeling lost? Understood

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Takeda buys into Amylin‘s weight-loss drug portfolio – Takeda will pay $75 million upfront for medicines including Amylin’s pramlintide/metreleptin and davalintide, in the second phase of testing needed for U.S. regulatory approval, Osaka- based Takeda and San Diego-based Amylin said in a statementmore Plus, quickie update on three other anti-obesity drugs being developed by various companies.

New lupus treatment (HGS/Glaxo) looking promising on pathway to approval – Human Genome Sciences Inc said its experimental lupus drug Benlysta was successful in a second large clinical trial, paving the way for approval of the first new treatment for the disease in 50 yearsmore

Vertex HepC drug cures 80%The hepatitis C cure rates of greater than 80% across all four patient groups of the study are also the highest ever recorded in any telaprevir study to date and exceed the cure rates reported in separate studies of boceprevir, a competing hepatitis C drug under development by Schering-Ploughmore

Let’s investigate: Amgen and Shire are the latest.

RECOMMENDED

Meetings. Event planning and execution, logistics, training. We can match you up with the ideal partner(s). Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Not counting on blockbusters – changes, and the future, at Sanofi-Aventis.

JUST FOR FUN

Bayer turns its headquarters into a giant billboard. Pretty eye-catching (watch the video clip).

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

FTC says “yes” to Merck-Schering merger.

AstraZeneca’s experimental drug Brilinta may not get along well with aspirin: AstraZeneca Plc is looking into whether greater use of aspirin reduces the effectiveness of its experimental clot-busting medicine Brilinta, which analysts had estimated would bring in $1 billion a yearmore Plus, AZ agrees to a $520M fine in Seroquel marketing probe. Ouch.

Medical Marketing and Media agency awards for this year. It was an in-house effort that picked up the Gold Award for Best Integration Program for Large Companies.

Statins and flu: med may be good for more than high cholesterol? – Doctors may have a new treatment for swine flu that’s already on pharmacy shelves — cholesterol-lowering statin drugs like Pfizer’s Lipitor and Zocor. Researchers reported Thursday that people who were already on these drugs when they caught seasonal flu and had to be hospitalized were twice as likely to survive than those not on such medicinesmore

RECOMMENDED

Train-the-Trainer. Impactiviti’s partner network includes a wonderful provider who can customize a train-the-trainer program for your department. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

When Statistics have Faces. A reminder of the humanity in everything we do. Also, an amazing animation of how the flu virus infects your body.

JUST FOR FUN

Landscape Photo of the Year. And other lovely contenders.
Coming up next week:

eComm

Nov. 3-4 – eyeforpharma’s 4th Annual eCommunication and On-line Marketing Summit, Philadelphia, PA. I’ll be part of a panel on social networking, and live-blogging/Twittering. Here’s a discount code to save $400 off your registration: SPEAK

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

TODAY’S NEWS

Novartis “brings back” a shizophrenia drug – The company is buying back the rights to a schizophrenia pill that it sold to another company years ago because Novartis thought it wasn’t worth pursuingmore

Amended complaint about Schering‘s knowledge of Vytorin ineffectiveness names names – The amended complaint, filed Oct. 1, 2009, rehashes all the claims about anonymous CafePharma commenters correctly predicting that Enhance was a dud. But it adds a tantalizing new ingredient: A “confidential informant” who has told lawyers in a related securities action who knew what and when inside Schering. The informant is one of “Schering-Plough’s senior medical personnel”more

RECOMMENDED

Specialty Sales Training workshops. Impactiviti’s partners can help you develop and deliver top-notch selling skills and territory management programs for your specialty sales force. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

Weariness. We all feel it sometimes. But then again, maybe hard work is overrated!

JUST FOR FUN

Shake-your-head-in-bewilderment sign that stems from the various state bans on gifts to physicians.

Coming up NEXT WEEK:

DigitalPharma

Oct. 19-21 - eXL’s Digital Pharma conference, Bridgewater, NJ. This event will be quite progressive, with more of an informal “unconference” format to maximize interaction. I’ll be co-leading a pre-conference workshop on the 19th on social media, and live-blogging/Twittering. Here’s a discount code for 15% your registration: P615WOO

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Amgen gets approval for one (but not another) indication for their new bone drug – Food and Drug Administration experts unanimously voted that Amgen’s injectable drug denosumab helps prevent bone fractures in women with postmenopausal osteoporosis. But panelists said the drug should only be used by patients who face the greatest risk of fractures. In a separate 12-3 vote, the panel ruled against using the drug as a preventive measure for women with low bone density…more

Schering gets approval for new shizophrenia drug – Schering-Plough Corp. said Friday that the U.S. Food and Drug Administration has approved Saphris tablets for acute treatment of schizophrenia in adults and acute treatment of manic or mixed episodes associated with bipolar disorder in adults. The pharmaceutical company said that Saphris is the first psychotropic drug to receive simultaneous initial approval for both indications…more

King‘s Embeda is approved by FDA: may help counteract pain-pill abuse – The Food and Drug Administration cleared the extended- release morphine product, Embeda, the agency said today in an e- mail. Embeda contains a chemical designed to counteract the morphine if the capsule is crushed, chewed or dissolved in alcohol to get the full dose at once. The company said, and the FDA agreed, the evidence wasn’t conclusive that the chemical truly interfered with the morphine high. More here at the WSJ Health blog.

Allergan‘s Latisse – maybe the new baldness treatment? Stay tuned!

I like to stay on top of early-on encouraging oncology advances. Many don’t pan out, of course. But this sort of result is a nice glimmer!

By the way…are you in need of a vendor/partner to help you develop specialty sales force training? Let me know and I can make a recommendation!

———-

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Twitter: @swoodruff

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.

Join 27 other followers